A two centers study of postoperative adjuvant chemotherapy with S-1 versus SOX/XELOX regimens for gastric cancer after D2 resection: a cohort study.

Song ZhengYao ZhouYangcheng SunZhen WangYidan Lu

Published in: Cancer chemotherapy and pharmacology (2019)

For patients with advanced gastric cancer who underwent D2 resection, compared with S-1 regimen, there is prolonged disease-free survival trend with SOX/XELOX regimen, while there is no significant overall survival benefit.

Keyphrases

free survival
transcription factor
stem cells
patients undergoing
neoadjuvant chemotherapy
lymph node
radiation therapy
rectal cancer